

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

# Single Technology Appraisal

### Vutrisiran for treating transthyretin-related amyloidosis cardiomyopathy [ID6470]

#### **Provisional Consultees** Provisional Commentators (no right to submit or appeal) General Company • All Wales Inherited Metabolic Disease Alnylam Pharmaceuticals (vutrisiran) Service Patient/carer groups All Wales Therapeutics and Toxicology • Amyloidosis UK Centre Arrythmia Alliance Allied Health Professionals Federation • • Atrial Fibrillation Association Association of Renal Industries • • British Society for Heart Failure Board of Community Health Councils in • **British Liver Trust** Wales • Cardiomyopathy UK British National Formulary • Cardiovascular Care Partnership **Care Quality Commission** • • Cell and Gene Therapy Catapult **Circulation Foundation** • . Department of Health - Northern Ireland • Gene People • Healthcare Improvement Scotland Genetic Alliance UK • • Medicines and Healthcare products HEART UK • Regulatory Agency • Liver4Life National Association of Primary Care **Pumping Marvellous** • • National Pharmacy Association Somerville Foundation • • **National Services Division** • South Asian Health Foundation • NHS Confederation • **Specialised Healthcare Alliance** • Scottish Medicines Consortium • Healthcare professional groups Welsh Government Association of Genetic Nurses and Welsh Health Specialised Services • Counsellors Committee British Cardiovascular Society **British Geriatrics Society** Comparator companies • Pfizer (tafamidis) British Nuclear Cardiology Society • British Society of Echocardiography • Relevant research groups British Society for Gene and Cell • Cochrane Heart Group Therapy **Genomics England** •

## Final Stakeholder List

British Society for Genetic Medicine •

- Haemochromatosis UK •
- National Heart and Lung Institute •
- Primary Care Cardiovascular Society •
  - National Institute for Health Research • **Royal College of General Practitioners**

•


MRC Clinical Trials Unit

**Preventions and Outcomes** 

National Centre for Cardiovascular

Final stakeholder list for the evaluation of vutrisiran for treating transthyretin-related amyloidosis cardiomyopathy [ID6470] Issue date: April 2025

© National Institute for Health and Care Excellence 2024. All rights reserved.



Provisional Consultees	Provisional Commentators (no right to submit or appeal)
<ul> <li>Royal College of Nursing</li> <li>Royal College of Pathologists</li> <li>Royal College of Physicians</li> <li>Royal Pharmaceutical Society</li> <li>Royal Society of Medicine</li> <li>UK Clinical Pharmacy Association</li> <li>Vascular Society of Great Britain and Ireland</li> </ul>	<ul> <li><u>Associated Public Health groups</u></li> <li>Public Health Wales</li> <li>UK Health Security Agency</li> </ul>
Others <ul> <li>Department of Health and Social Care</li> <li>NHS England</li> </ul>	

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

#### **Definitions:**

Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.


#### **Consultees**

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

#### **Commentators**



Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.